Two Seas Capital LP Sells 31,500 Shares of Roivant Sciences Ltd. $ROIV

Key Points

• Two Seas Capital LP reduced its holdings in Roivant Sciences by 0.3%, now owning approximately 10.1 million shares, which constitutes 3.2% of its portfolio.
• Several institutional investors, including Bank of New York Mellon Corp and GAMMA Investing LLC, significantly increased their positions in Roivant Sciences during the same period.
• Roivant Sciences' stock has a current price of $12.92, with analysts setting price targets ranging from $16.00 to $19.00 following recent upgrades.

Two Seas Capital LP decreased its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 0.3% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,136,307 shares of the company's stock after selling 31,500 shares during the period. Roivant Sciences makes up about 3.2% of Two Seas Capital LP's investment portfolio, making the stock its 3rd largest position. Two Seas Capital LP owned 1.42% of Roivant Sciences worth $102,275,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Cutter Capital Management LP purchased a new stake in shares of Roivant Sciences during the first quarter valued at $13,117,000. Amundi grew its stake in Roivant Sciences by 18.1% in the 1st quarter. Amundi now owns 398,729 shares of the company's stock worth $3,991,000 after acquiring an additional 61,214 shares in the last quarter. PDT Partners LLC increased its position in shares of Roivant Sciences by 11.9% during the first quarter. PDT Partners LLC now owns 568,891 shares of the company's stock worth $5,740,000 after acquiring an additional 60,460 shares during the period. Troluce Capital Advisors LLC bought a new stake in shares of Roivant Sciences during the first quarter valued at approximately $7,187,000. Finally, Caption Management LLC boosted its holdings in shares of Roivant Sciences by 70.7% in the first quarter. Caption Management LLC now owns 256,661 shares of the company's stock valued at $2,590,000 after purchasing an additional 106,323 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Price Performance

NASDAQ ROIV traded down $0.26 on Friday, hitting $14.15. The stock had a trading volume of 3,382,142 shares, compared to its average volume of 5,910,471. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $14.48. The business's fifty day moving average price is $11.80 and its 200 day moving average price is $11.11. The stock has a market cap of $9.66 billion, a price-to-earnings ratio of -20.21 and a beta of 1.15.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 385,816 shares of the business's stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $12.96, for a total transaction of $5,000,175.36. Following the sale, the insider owned 35,508,359 shares of the company's stock, valued at approximately $460,188,332.64. The trade was a 1.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Eric Venker sold 100,000 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $11.72, for a total transaction of $1,172,000.00. Following the transaction, the chief executive officer owned 1,653,585 shares in the company, valued at $19,380,016.20. The trade was a 5.70% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,218,022 shares of company stock valued at $39,010,006. 10.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on ROIV. Citigroup assumed coverage on Roivant Sciences in a report on Tuesday, September 2nd. They set a "buy" rating and a $16.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, June 18th. Finally, The Goldman Sachs Group upgraded shares of Roivant Sciences to a "strong-buy" rating and set a $19.00 target price on the stock in a report on Thursday, July 10th. Two analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to data from MarketBeat.com, Roivant Sciences presently has a consensus rating of "Strong Buy" and an average target price of $17.67.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.